We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cangene Acquires Twinstrand Therapeutics Inc.
News

Cangene Acquires Twinstrand Therapeutics Inc.

Cangene Acquires Twinstrand Therapeutics Inc.
News

Cangene Acquires Twinstrand Therapeutics Inc.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cangene Acquires Twinstrand Therapeutics Inc."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cangene Corporation has announces that it has acquired all issued and outstanding shares of privately held Twinstrand Therapeutics Inc. Cangene has paid $1.5 million to acquire Twinstrand which has products, technologies and financial attributes including those related to tax.

Twinstrand has established a technology that uses modified versions of ricin, a plant-derived cell toxin, as therapeutic prodrugs. Its lead drug, a product known as TST10088, is currently undergoing a Phase I clinical trial. The prodrugs leave healthy cells unaffected while specific chemical activity within targeted diseased cells activates the cell-killing activities of the drug.

As a spin-off from its original focus, Twinstrand has also begun developing anti-ricin, antibody-based therapeutics; Cangene has partnered with Twinstrand on this technology in the past.

The acquisition of Twinstrand includes an obligation that Cangene pay to certain of Twinstrand's former investors a royalty on any commercial sales of antibody products related to TST10088 that may be developed, as well as a royalty on any associated licensing fees.

"This acquisition is in line with our on-going interest in augmenting our commercial pipeline and biodefence products through the acquisition of complementary products or technologies," said Dr. John Langstaff, Cangene's president and CEO.
Advertisement